Literature DB >> 31166615

Glucagon up-regulates hepatic mitochondrial pyruvate carrier 1 through cAMP-responsive element-binding protein; inhibition of hepatic gluconeogenesis by ginsenoside Rb1.

Meng-Die Lou1, Jia Li1, Yao Cheng1, Na Xiao2, Gaoxiang Ma1, Ping Li1, Baolin Liu1, Qun Liu1, Lian-Wen Qi1,3.   

Abstract

BACKGROUND AND
PURPOSE: Hepatic mitochondrial pyruvate carrier (MPC) transports pyruvate into mitochondria. This study investigated the involvement of MPC1 in hepatic glucagon response, in order to identify a possible pharmacological intervention. EXPERIMENTAL APPROACH: The correlation between hepatic glucagon response and MPC1 induction was investigated in fasted mice and primary hepatocytes. The effects of ginsenoside Rb1 on MPC1 function were observed. KEY
RESULTS: Glucagon challenge raised blood glucose with hepatic MPC1 induction, and inhibition of MPC induction coincided with a reduced rise in blood glucose. cAMP-responsive element-binding protein (CREB) knockdown blocked glucagon-induced MPC1 expression, while CREB overexpression increased MPC1 expression. Luciferase reporter, chromatin immunoprecipitation assay, and promoter mutation confirmed that CREB increased MPC1 transcription through gene promoter induction. CREB regulated transcription co-activator 2 nuclear translocation was also required for CREB to promote MPC1 induction. Glucagon shifted mitochondrial pyruvate towards carboxylation for gluconeogenesis via the opposite regulation of pyruvate dehydrogenase and carboxylase with respect to MPC1 induction. MPC1 induction was necessary for glucagon to promote pyruvate-driven hepatic glucose production (HGP), but glucagon failed to influence HGP from other gluconeogenic substrates routed into the tricarboxylic acid cycle, independent of MPC. Rb1 blocked cAMP signalling by inhibiting AC activity and deactivated CREB by dephosphorylation, possibly contributing to inhibiting MPC1 induction to reduce HGP. CONCLUSIONS AND IMPLICATIONS: CREB transcriptionally up-regulates MPC1 to provide pyruvate for gluconeogenesis. Rb1 reduced cAMP formation which consequently reduced CREB-mediated MPC1 induction and thereby might contribute to limiting pyruvate-dependent HGP. These results suggest a therapeutic strategy to reduce hyperglycaemia in diabetes.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31166615      PMCID: PMC6637041          DOI: 10.1111/bph.14758

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

Review 1.  Recycling of glucose and determination of the Cori Cycle and gluconeogenesis.

Authors:  J Katz; J A Tayek
Journal:  Am J Physiol       Date:  1999-09

Review 2.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

3.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 4.  The mitochondrial pyruvate carrier in health and disease: To carry or not to carry?

Authors:  Tom Bender; Jean-Claude Martinou
Journal:  Biochim Biophys Acta       Date:  2016-01-26

5.  Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2.

Authors:  Renaud Dentin; Yi Liu; Seung-Hoi Koo; Susan Hedrick; Thomas Vargas; Jose Heredia; John Yates; Marc Montminy
Journal:  Nature       Date:  2007-09-05       Impact factor: 49.962

6.  The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism.

Authors:  Seung-Hoi Koo; Lawrence Flechner; Ling Qi; Xinmin Zhang; Robert A Screaton; Shawn Jeffries; Susan Hedrick; Wu Xu; Fayçal Boussouar; Paul Brindle; Hiroshi Takemori; Marc Montminy
Journal:  Nature       Date:  2005-09-07       Impact factor: 49.962

Review 7.  Regulation of pyruvate metabolism in metabolic-related diseases.

Authors:  Nam Ho Jeoung; Chris R Harris; Robert A Harris
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

8.  Alanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity.

Authors:  Rong-Ze Yang; Soohyun Park; William J Reagan; Rick Goldstein; Shao Zhong; Michael Lawton; Francis Rajamohan; Kun Qian; Li Liu; Da-Wei Gong
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

9.  Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier.

Authors:  Ajit S Divakaruni; Sandra E Wiley; George W Rogers; Alexander Y Andreyev; Susanna Petrosyan; Mattias Loviscach; Estelle A Wall; Nagendra Yadava; Alejandro P Heuck; David A Ferrick; Robert R Henry; William G McDonald; Jerry R Colca; Melvin I Simon; Theodore P Ciaraldi; Anne N Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-19       Impact factor: 11.205

10.  A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange.

Authors:  Yi Liu; Renaud Dentin; Danica Chen; Susan Hedrick; Kim Ravnskjaer; Simon Schenk; Jill Milne; David J Meyers; Phil Cole; John Yates; Jerrold Olefsky; Leonard Guarente; Marc Montminy
Journal:  Nature       Date:  2008-10-05       Impact factor: 49.962

View more
  7 in total

1.  Glucagon up-regulates hepatic mitochondrial pyruvate carrier 1 through cAMP-responsive element-binding protein; inhibition of hepatic gluconeogenesis by ginsenoside Rb1.

Authors:  Meng-Die Lou; Jia Li; Yao Cheng; Na Xiao; Gaoxiang Ma; Ping Li; Baolin Liu; Qun Liu; Lian-Wen Qi
Journal:  Br J Pharmacol       Date:  2019-07-06       Impact factor: 8.739

Review 2.  The mitochondrial pyruvate carrier at the crossroads of intermediary metabolism.

Authors:  Nicole K H Yiew; Brian N Finck
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-05-30       Impact factor: 5.900

3.  HIV-1 gp120 Impairs Spatial Memory Through Cyclic AMP Response Element-Binding Protein.

Authors:  Jenny Shrestha; Maryline Santerre; Charles N S Allen; Sterling P Arjona; Carmen Merali; Ruma Mukerjee; Kumaraswamy Naidu Chitrala; Jin Park; Asen Bagashev; Viet Bui; Eliseo A Eugenin; Salim Merali; Marcus Kaul; Jeannie Chin; Bassel E Sawaya
Journal:  Front Aging Neurosci       Date:  2022-05-09       Impact factor: 5.702

Review 4.  Ginsenoside from ginseng: a promising treatment for inflammatory bowel disease.

Authors:  Zengping Kang; Youbao Zhonga; Tiantian Wu; Jiaqi Huang; Haimei Zhao; Duanyong Liu
Journal:  Pharmacol Rep       Date:  2021-01-19       Impact factor: 3.024

5.  MicroRNA-137-3p Improves Nonalcoholic Fatty Liver Disease through Activating AMPKα.

Authors:  Yuanjie Yu; Chunping He; Shiyun Tan; Mengjun Huang; Yitian Guo; Ming Li; Qian Zhang
Journal:  Anal Cell Pathol (Amst)       Date:  2021-12-29       Impact factor: 2.916

Review 6.  Mitochondrial Pyruvate Carrier Function in Health and Disease across the Lifespan.

Authors:  Jane L Buchanan; Eric B Taylor
Journal:  Biomolecules       Date:  2020-08-08

Review 7.  Recent progress (2015-2020) in the investigation of the pharmacological effects and mechanisms of ginsenoside Rb1, a main active ingredient in Panax ginseng Meyer.

Authors:  Zuan Lin; Rongfang Xie; Chenhui Zhong; Jianyong Huang; Peiying Shi; Hong Yao
Journal:  J Ginseng Res       Date:  2021-07-30       Impact factor: 6.060

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.